Vallon Pharmaceuticals Competitors

Longeveron (NASDAQ:LGVN) and Vallon Pharmaceuticals (NASDAQ:VLON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Profitability

This table compares Longeveron and Vallon Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Longeveron and Vallon Pharmaceuticals, as reported by MarketBeat.

Valuation & Earnings

This table compares Longeveron and Vallon Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Evaxion Biotech A/S (NASDAQ:EVAX) and Vallon Pharmaceuticals (NASDAQ:VLON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Valuation & Earnings

This table compares Evaxion Biotech A/S and Vallon Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Evaxion Biotech A/S and Vallon Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Evaxion Biotech A/S and Vallon Pharmaceuticals, as reported by MarketBeat.

Evaxion Biotech A/S presently has a consensus target price of $18.00, indicating a potential upside of 146.24%. Given Evaxion Biotech A/S's higher possible upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Vallon Pharmaceuticals.

Summary

Evaxion Biotech A/S beats Vallon Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Universe Pharmaceuticals (NYSE:UPC) and Vallon Pharmaceuticals (NASDAQ:VLON) are both small-cap companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Valuation and Earnings

This table compares Universe Pharmaceuticals and Vallon Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Universe Pharmaceuticals and Vallon Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for Universe Pharmaceuticals and Vallon Pharmaceuticals, as reported by MarketBeat.com.

Viridian Therapeutics (NASDAQ:VRDN) and Vallon Pharmaceuticals (NASDAQ:VLON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Profitability

This table compares Viridian Therapeutics and Vallon Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for Viridian Therapeutics and Vallon Pharmaceuticals, as reported by MarketBeat.com.

Viridian Therapeutics presently has a consensus target price of $34.00, indicating a potential upside of 132.56%. Given Viridian Therapeutics' higher possible upside, equities research analysts clearly believe Viridian Therapeutics is more favorable than Vallon Pharmaceuticals.

Valuation and Earnings

This table compares Viridian Therapeutics and Vallon Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Summary

Viridian Therapeutics beats Vallon Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Vallon Pharmaceuticals (NASDAQ:VLON) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Vallon Pharmaceuticals and Inhibikase Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Vallon Pharmaceuticals and Inhibikase Therapeutics, as provided by MarketBeat.

Valuation & Earnings

This table compares Vallon Pharmaceuticals and Inhibikase Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Vallon Pharmaceuticals (NASDAQ:VLON) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Vallon Pharmaceuticals and Virios Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Vallon Pharmaceuticals and Virios Therapeutics, as provided by MarketBeat.

Valuation & Earnings

This table compares Vallon Pharmaceuticals and Virios Therapeutics' top-line revenue, earnings per share (EPS) and valuation.